Besides, further clinical studies are warranted to ascertain the potential therapeutic utility of Gln metabolic pathways for PCa radiosensitization and the implication of Gln plasma levels as well as MYC and GLS1 expression levels as biomarkers of tumor aggressiveness and recurrence after radiotherapy. The gene discussed is MYC; the disease is neoplasm.